Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$2.77 +2.2%	$2.31	$1.47 ▼ $17.31	$67.67M	N/A	225,397 shs	29,248 shs
AVIR Atea Pharmaceuticals	$3.53 +0.9%	$3.51	$2.45 ▼ $4.14	$280.14M	0.25	385,478 shs	233,288 shs
DBVT DBV Technologies	$9.54 -2.7%	$9.79	$2.20 ▼ $12.78	$261.30M	-0.58	203,752 shs	24,781 shs
SGMT Sagimet Biosciences	$7.35 +2.4%	$8.72	$1.73 ▼ $11.41	$225.42M	3.37	1.10 million shs	380,743 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-2.87%	+1.50%	+6.27%	+36.87%	-73.14%
AVIR Atea Pharmaceuticals	+0.29%	0.00%	+2.04%	+22.81%	-7.89%
DBVT DBV Technologies	+1.07%	-0.35%	+3.95%	+12.60%	+117.03%
SGMT Sagimet Biosciences	+3.91%	-25.05%	-18.69%	+110.56%	+136.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.7912 of 5 stars	3.5	0.0	1.5	2.5	1.3
AVIR Atea Pharmaceuticals	1.7722 of 5 stars	3.3	0.0	0.6	2.5	1.3
DBVT DBV Technologies	3.3198 of 5 stars	3.4	5.0	2.0	2.5	0.6
SGMT Sagimet Biosciences	3.3684 of 5 stars	3.5	4.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.00	513.72% Upside
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	69.97% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	54.61% Upside
SGMT Sagimet Biosciences	3.00	Buy	$25.67	249.21% Upside

Current Analyst Ratings Breakdown

Latest ARTV, DBVT, AVIR, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	SGMT Sagimet Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
8/7/2025	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$29.00
7/24/2025	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	270.68	N/A	N/A	$6.10 per share	0.45
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$4.59 per share	N/A
DBVT DBV Technologies	$4.15M	62.96	N/A	N/A	$3.15 per share	3.03
SGMT Sagimet Biosciences	$2M	112.71	N/A	N/A	$4.24 per share	1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	N/A
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	11/5/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.83	N/A	N/A	N/A	N/A	-39.88%	-38.40%	N/A

Latest ARTV, DBVT, AVIR, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.52	-$0.32	+$0.20	-$0.32	N/A	N/A
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
DBVT DBV Technologies	N/A	2.45	2.45
SGMT Sagimet Biosciences	N/A	17.55	17.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
AVIR Atea Pharmaceuticals	86.67%
DBVT DBV Technologies	71.74%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
AVIR Atea Pharmaceuticals	18.10%
DBVT DBV Technologies	1.44%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable

ARTV, DBVT, AVIR, and SGMT Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by Brokerages

August 21 at 3:14 AM | marketbeat.com

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

August 20 at 1:01 PM | zacks.com

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

August 20 at 10:36 AM | zacks.com

What is Wedbush's Estimate for SGMT Q2 Earnings?

August 16, 2025 | marketbeat.com

Q2 Earnings Estimate for SGMT Issued By Wedbush

August 16, 2025 | americanbankingnews.com

Sagimet Biosciences Enters New Sales Agreement with Leerink

August 15, 2025 | msn.com

Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025 | finanznachrichten.de

Sagimet Biosciences Tops Q2 EPS Forecast

August 13, 2025 | aol.comA

Sagimet Biosciences Reports Positive Phase 3 Results for Denifanstat in Acne and Initiates Phase 1 Trials for FASN Inhibitors

August 13, 2025 | quiverquant.comQ

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025 | globenewswire.com

Wedbush Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation

August 12, 2025 | msn.com

Wedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT)

August 12, 2025 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Wedbush

August 12, 2025 | americanbankingnews.com

Sagimet Biosciences (SGMT) to Release Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Sagimet Biosciences initiated with an Outperform at Wedbush

August 11, 2025 | msn.com

What is HC Wainwright's Estimate for SGMT Q2 Earnings?

August 11, 2025 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Upgraded at HC Wainwright

August 10, 2025 | americanbankingnews.com

Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright

August 8, 2025 | marketbeat.com

Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday

August 6, 2025 | marketbeat.com

Sagimet Biosciences Inc. to Participate in Canaccord Genuity 45th Annual Growth Conference on August 13, 2025

August 5, 2025 | quiverquant.comQ

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV, DBVT, AVIR, and SGMT Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$2.77 +0.06 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$2.79 +0.02 (+0.72%)

As of 04:10 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Atea Pharmaceuticals NASDAQ:AVIR

$3.53 +0.03 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 -0.01 (-0.28%)

As of 04:20 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.87 +0.07 (+0.71%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Sagimet Biosciences NASDAQ:SGMT

$7.35 +0.17 (+2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$7.35 0.00 (0.00%)

As of 04:42 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time